Literature DB >> 21029496

[Guideline 'Diagnosis and treatment of inflammatory bowel disease in adults'. I. Diagnosis and treatment].

Ad A van Bodegraven1, Jannes J E van Everdingen, Gerard Dijkstra, Dirk J de Jong, Bas Oldenburg, Daan W Hommes.   

Abstract

The Dutch national practice guideline 'Diagnosis and treatment of inflammatory bowel diseases (IBD) in adults' describes the multidisciplinary approach for adult patients with (suspected) IBD, recommended following analysis of the literature according to the principles of evidence based guideline development. The symptoms on first presentation of a patient with IBD are mainly connected with the localisation and severity of the disease and less with the resulting diagnosis 'Crohn's disease' or 'ulcerative colitis'. There is no test by which the diseases can be distinguished with certainty. Clinical course, ileocolonoscopy and histopathological investigation following biopsy form the 'gold standard' for diagnosis of IBD. The final diagnostic step is disease assessment according to the Montreal classification in order to enable unambiguous communication with medical professionals. The first aim of treatment is to treat and stabilise active disease (induction therapy); at the same time maintenance therapy is initiated. A step-up approach is recommended for both treatment aims. Surgical intervention is indicated if the medical treatment is ineffective, in case of intractable gastrointestinal bleeding, in clinically significant gastrointestinal stenosis due to fibrotic scar tissue, or if complications of the inflammation occur such as abscess, peritonitis, or complicated fistula formation. Nutrition and diet do not play a primary therapeutic role in treatment of adult patients with IBD. However, supportive nutritional care is warranted. Probiotics have a demonstrable effect in preventing pouchitis, but not in the treatment of IBD. Alternative medicine has no role to play in the treatment of IBD. The risk of developing colorectal carcinoma is slightly elevated in IBD patients. Therefore, endoscopic surveillance strategies, aimed at early detection of dysplasia, is indicated according to a schedule in which the frequency increases according to the time elapsed since first clinical signs of IBD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029496

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  9 in total

1.  Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Vince B C Biemans; Tim R A van den Heuvel; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2018-01-09       Impact factor: 10.864

2.  Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Tim R A van den Heuvel; Limmie Y L Liu; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2016-12-06       Impact factor: 10.864

3.  Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.

Authors:  Andrea L Matthis; Bin Zhang; Lee A Denson; Bruce R Yacyshyn; Eitaro Aihara; Marshall H Montrose
Journal:  Inflamm Bowel Dis       Date:  2016-08       Impact factor: 5.325

Review 4.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 5.  How I treat my inflammatory bowel disease-patients with thiopurines?

Authors:  Berrie Meijer; Chris Jj Mulder; Adriaan A van Bodegraven; Nanne K H de Boer
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

Review 6.  Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy.

Authors:  Margien L Seinen; Geerten P van Nieuw Amerongen; Nanne K H de Boer; Adriaan A van Bodegraven
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

7.  Association between ulcerative colitis and Helicobacter pylori infection: A case-control study.

Authors:  Iyad Ali; Qusay Abdo; Shayma'a M Al-Hihi; Ansam Shawabkeh
Journal:  Heliyon       Date:  2022-02-09

8.  Contrast Enhanced Abdominal Ultrasound in the Assessment of Ileal Inflammation in Crohn's Disease: A Comparison with MR Enterography.

Authors:  C S Horjus Talabur Horje; R Bruijnen; L Roovers; M J M Groenen; F B M Joosten; P J Wahab
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

9.  Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study.

Authors:  L J T Smits; R W M Pauwels; W Kievit; D J de Jong; A C de Vries; F Hoentjen; C J van der Woude
Journal:  BMJ Open       Date:  2020-05-26       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.